

Curriculum Vitae
Mark Alan Porter, M.D.

EDUCATION

University of Alabama Birmingham, Alabama	Neuromuscular/Neurophysiology Fellowship 1982-1983
Baylor College of Medicine Houston, Texas	Neurology Residency 1979-1982
Baylor College of Medicine Houston, Texas	Internship 1978-1979
Northwestern University School of Medicine Chicago, Illinois	Doctor of Medicine 1978
St. Olaf College Northfield, Minnesota	BA Cum Laude, Chemistry 1974

SITE AFFILIATION

DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

PROFESSIONAL EXPERIENCE

Founder and Medical Director Piedmont Hospital Stroke Center Rock Hill, South Carolina	2010-Oct 2016
Clinical Neurologist/Partner Metrolina Neurological Associates, PA Rock Hill, South Carolina (Special emphasis on Botox and Stroke)	2001-present
Partner Metrolina Neurodiagnostic Center Rock Hill, South Carolina	2006-present
Botox Injector (Mentored by Dr. Mitchell Brin, Columbia University Medical School, New York City)	1989-present
Clinical Neurologist/Partner Fort Wayne Neurological Center Fort Wayne, Indiana (Special interest and training in Neuromuscular Disease, Nerve and Muscle Biopsy, and Neurological Rehabilitation)	1983-2001

Medical Director 1983-2001
Neurology Laboratory
Fort Wayne Neurological Center

Medical Director 1999-2001
Wissman Stroke Center
Parkview Hospital
Fort Wayne, Indiana

Director of Traumatic Brain Program 1995-2001
Parkview Hospital
Fort Wayne, Indiana

Medical Director 1990-2001
Out-Patient Rehabilitation Center
Parkview Hospital
Fort Wayne, Indiana

Founder and Director 1982-1983
VA Hospital Headache Clinic
Houston, Texas

Board of Directors/President 1998-2001
Allied Physicians, Inc.
Fort Wayne, Indiana

Board of Directors 1999-2001
Anthony Wayne Services/Easter Seals
(Services for individuals with mental and physical disabilities)
Fort Wayne, Indiana

PUBLICATIONS

Benign Coital Cephalalgia, Differential Diagnosis and Treatment, Archives of Neurology, 1981. Vol. 38, p.710-712.

CERTIFICATIONS

American Board of Psychiatry and Neurology 1984

MEMBERSHIPS

American Academy of Neurology

AAEM

MEDICAL LICENSURE

North Carolina
South Carolina

TEACHING EXPERIENCE

Selected Member 2015-2020
Academy of Educators
University of North Carolina School of Medicine

Adjunct Professor of Neurology 2013-2016
University of North Carolina Medical School
Charlotte, North Carolina

Instructor of Neurology 1990-2001
Indiana University School of Medicine
Fort Wayne, Indiana Campus

CLINICAL RESEARCH

Luitpold Pharmaceuticals, Inc. 2016
A Double-Blind, Multi-Center, Randomized, Placebo-
Controlled Study to Investigate the Efficacy and Safety
of Injectafer (Ferric Carboxymaltose) in the Treatment
of Restless Leg Syndrome
Sub-Investigator

Eli Lilly & Company - Protocol I5Q-MC-CGAG 2016
A phase 3, randomized, double-blind, placebo-controlled
study of LY2951742 in patients with Episodic migraine-the
EVOLVE-1 study
Principal Investigator

AZTherapies - Protocol AZT-001 2016
A phase III safety and efficacy study of
AZT-OP1 in subjects with evidence of early Alzheimer's disease
Sub-Investigator

Biogen Idec MA, Inc - Protocol 218MS305 2015
A multicenter, randomized, double-blind, placebo controlled
study to assess the long-term efficacy and safety of prolonged
release fampridine (BIIB041) 10 mg, administered twice daily in
subjects with multiple sclerosis (ENHANCE)
Sub-Investigator

Chase Pharmaceuticals Corporation 2015
Phase II, Ascending Dose Study for Alzheimer's Dementia
Principal Investigator

Allergan – Protocol GMA-BTX-SP-12-001 2014
AsPIRE: Adult SPasticity International REGistry on BOTOX Treatment
Principal Investigator

Novartis Pharmaceuticals – Protocol CFTY720D2403 Passage 2014
Long-term, prospective, multinational, parallel-cohort study monitoring

safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy
Sub-Investigator

Novartis Pharmaceuticals – Protocol CFTY720D2405 – Transition 2014
A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod
Sub-Investigator

Allergan/Botox and Migraine Headache Study 2001
Principal Investigator

ASTRA-MEDICA Chronic Pain Study Protocol #h-01066-3121 1999
Sub-Investigator

Imitrex Migraine Study 2000
Principal Investigator

COMTAN Parkinson's Study 2000
Principal Investigator

Pfizer Stroke Treatment Study 0-8 Hour Window 2000
Sub-Investigator

Daichi Post Stroke Depression Study 1999
Sub-Investigator

Fujisawa Alzheimer's Study 1999
Sub-Investigator

Allergan/BOTOX-Chronic Low Back Pain Study 1999
Principal Investigator

M.I.N.T. Alzheimer's Study 1998
Principal Investigator

Gain III Stroke Treatment Study 0-6 Hour Window 1998
Sub-Investigator


Fiblast Stroke Treatment Study 0-6 Hour Window 1997
Sub-Investigator

Gait II Stroke Treatment Study 0-12 Hour Window 1997
Sub-Investigator


Topiramate Epilepsy Trial 1997
Sub-Investigator

Atlantis Stroke Treatment Study (tPA) 3-5 Hour Window Sub-Investigator	1996
Allergan Purified Neurotoxin Complex, Botox For Spasticity in Legs Principal Investigator	1995
Neurontin Dosage Increase Principal Investigator	1995
Genentech Growth Hormone Study (Children with Down Syndrome)	1993
Stroke Treatment with Ancrod Trial 0-3 Hour Window Sub- Investigator	1992
Thrombolytic Therapy in Acute Ischemic Stroke (tPA) 0-3 Hour Window Sub-Investigator	1992

My signature verifies the information in these curriculum vitae is accurate and updated annually.



Mark A. Porter, MD



Date

